María Dolores Martín and Helena Moza, heads of the Preventive Medicine Service and the Immunization Unit of the Quirónsalud hospital network in the Community of Madrid.
Bad monoclonal antibodies make a very powerful tool, present and future, as method of immunization effective passive against infectious diseases and, in particular, against the infection of Covid-19. This is one of the maxims that was revealed during the first conference on ‘The Role of Preventive Medicine Services in Immunization’, organized by Jimenez Diaz Foundation.
In that sense, Helena Mozahead of the Immunization Unit of the Preventive Medicine Service of the four Quirónsalud hospitals integrated into the public network of Madrid, indicated that “we have approval to use Evusheld (AZD7442), a combination of two monoclonal antibodies Long-acting IgG1k, cilgavimab and tixagevimab, derived from B cells of convalescent patients with SARS-CoV-2 infection”. The joint administration of these two antibodies is included in Vaccination strategy Spanish against Covid-19, as a complement to vaccination in persons with a high degree of immunosuppression.
Maria Dolores Martinfor her part, the head of the Preventive Medicine Service of the four Quirónsalud hospitals integrated into the Madrid public network of the aforementioned network of hospitals, assured that one of the commitments reached at the conference ” group formation of work and training strategies to continue working on the implementation of this type of therapy, as well as on other aspects related to immunization by our services”, and adds that the workshop “was a starting point for new meetings, which causes immense satisfaction”.
The conference highlighted “important research work” and clinical trials that have been conducted in the last year, and thanks to them, immunization-based prevention strategies have “noticeably” increased which they seek to protect the most vulnerable populations after SARS-Cov2 infection.
In that sense, Helena Mozaestablishes three currently available preventive methods: “vaccines for use in primary series and boosters, which offer protection against serious diseases; the vaccines adapted to new variants, to strengthen the immune response and therefore protect against all clinical manifestations; and passive immunization through the administration of prophylactic drugs for high-risk persons who do not respond to vaccination and which some hospitals in different autonomous communities have already accepted as a new service in their consultations”.
Although it may contain statements, data or notes from health institutions or experts, the information contained in Medical Writing is edited and prepared by journalists. We recommend that the reader consult a health professional for all health-related questions.